UroGen Pharma Ltd. Operating Cash Flow
UroGen Pharma Ltd. (URGN) reported Operating Cash Flow of -$78.32 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- UroGen Pharma Ltd. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$33.01M.
- UroGen Pharma Ltd. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$45.32M.
- UroGen Pharma Ltd. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$38.33M.
- UroGen Pharma Ltd. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$42.27M.
- UroGen Pharma Ltd. net cash provided by (used in) operating activities for fiscal 2025 was -$162.44M.
- UroGen Pharma Ltd. net cash provided by (used in) operating activities for fiscal 2024 was -$96.77M.
- UroGen Pharma Ltd. net cash provided by (used in) operating activities for fiscal 2023 was -$76.38M.
- UroGen Pharma Ltd. net cash provided by (used in) operating activities for fiscal 2022 was -$87.56M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$33.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$78.32M 10-Q · filed 2026-08-05 | -$116.65M derived: sum of 3 quarters · filed 2026-08-05 | -$158.92M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | -$45.32M 10-Q · filed 2026-05-06 | -$83.64M derived: sum of 2 quarters · filed 2026-05-06 | -$125.91M derived: sum of 3 quarters · filed 2026-05-06 | -$165.74M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | -$38.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$80.59M derived: sum of 2 quarters · filed 2026-03-02 | -$120.42M derived: sum of 3 quarters · filed 2026-08-05 | -$162.44M 10-K · filed 2026-03-02 | |
| 2025-09-30 | -$42.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$82.09M derived: sum of 2 quarters · filed 2026-08-05 | -$124.12M 10-Q · filed 2025-11-06 | -$137.74M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | -$39.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$81.85M 10-Q · filed 2026-08-05 | -$95.47M derived: sum of 3 quarters · filed 2026-08-05 | -$123.13M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | -$42.02M 10-Q · filed 2026-05-06 | -$55.64M derived: sum of 2 quarters · filed 2026-05-06 | -$83.31M derived: sum of 3 quarters · filed 2026-05-06 | -$107.06M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | -$13.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$41.28M derived: sum of 2 quarters · filed 2026-03-02 | -$65.03M derived: sum of 3 quarters · filed 2026-03-02 | -$96.77M 10-K · filed 2026-03-02 | |
| 2024-09-30 | -$27.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$51.41M derived: sum of 2 quarters · filed 2025-11-06 | -$83.15M 10-Q · filed 2025-11-06 | -$96.14M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | -$23.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$55.48M 10-Q · filed 2025-08-07 | -$68.48M derived: sum of 3 quarters · filed 2025-08-07 | -$85.78M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | -$31.73M 10-Q · filed 2025-05-12 | -$44.73M derived: sum of 2 quarters · filed 2025-05-12 | -$62.03M derived: sum of 3 quarters · filed 2025-05-12 | -$82.30M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | -$13.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$30.30M derived: sum of 2 quarters · filed 2025-03-10 | -$50.57M derived: sum of 3 quarters · filed 2025-03-10 | -$76.38M 10-K · filed 2025-03-10 | |
| 2023-09-30 | -$17.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$37.57M derived: sum of 2 quarters · filed 2024-11-06 | -$63.38M 10-Q · filed 2024-11-06 | -$85.13M derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-06-30 | -$20.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$46.08M 10-Q · filed 2024-08-13 | -$67.83M derived: sum of 3 quarters · filed 2024-08-13 | -$85.44M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | -$25.81M 10-Q · filed 2024-05-13 | -$47.56M derived: sum of 2 quarters · filed 2024-05-13 | -$65.17M derived: sum of 3 quarters · filed 2024-05-13 | -$89.37M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | -$21.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$39.36M derived: sum of 2 quarters · filed 2024-03-14 | -$63.56M derived: sum of 3 quarters · filed 2024-03-14 | -$87.56M 10-K · filed 2024-03-14 | |
| 2022-09-30 | -$17.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$41.81M derived: sum of 2 quarters · filed 2023-11-14 | -$65.81M 10-Q · filed 2023-11-14 | -$85.88M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | -$24.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$48.20M 10-Q · filed 2023-08-10 | -$68.27M derived: sum of 3 quarters · filed 2023-08-10 | -$86.74M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | -$24.00M 10-Q · filed 2023-05-11 | -$44.07M derived: sum of 2 quarters · filed 2023-05-11 | -$62.54M derived: sum of 3 quarters · filed 2023-05-11 | -$81.49M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$20.07M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$38.55M derived: sum of 2 quarters · filed 2023-03-24 | -$57.49M derived: sum of 3 quarters · filed 2023-03-24 | -$84.89M 10-K · filed 2023-03-24 | |
| 2021-09-30 | -$18.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$37.42M derived: sum of 2 quarters · filed 2022-11-10 | -$64.82M 10-Q · filed 2022-11-10 | -$86.06M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | -$18.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$46.35M 10-Q · filed 2022-08-11 | -$67.59M derived: sum of 3 quarters · filed 2022-08-11 | -$92.67M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$27.40M 10-Q · filed 2022-05-10 | -$48.64M derived: sum of 2 quarters · filed 2022-05-10 | -$73.72M derived: sum of 3 quarters · filed 2022-05-10 | -$97.65M derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$21.24M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$46.32M derived: sum of 2 quarters · filed 2022-03-21 | -$70.25M derived: sum of 3 quarters · filed 2022-03-21 | -$105.89M 10-K · filed 2022-03-21 | |
| 2020-09-30 | -$25.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$49.01M derived: sum of 2 quarters · filed 2021-11-15 | -$84.64M 10-Q · filed 2021-11-15 | -$110.64M derived: sum of 4 quarters · filed 2021-11-15 | |
| 2020-06-30 | -$23.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$59.56M 10-Q · filed 2021-08-04 | -$85.56M derived: sum of 3 quarters · filed 2021-08-04 | -$98.09M derived: sum of 4 quarters · filed 2021-08-04 | |
| 2020-03-31 | -$35.63M 10-Q · filed 2021-05-13 | -$61.63M derived: sum of 2 quarters · filed 2021-05-13 | -$74.16M derived: sum of 3 quarters · filed 2021-05-13 | -$88.72M derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | -$26.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | -$38.53M derived: sum of 2 quarters · filed 2021-03-18 | -$53.08M derived: sum of 3 quarters · filed 2021-03-18 | -$71.02M 10-K · filed 2021-03-18 | |
| 2019-09-30 | -$12.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$27.08M derived: sum of 2 quarters · filed 2020-11-09 | -$45.02M 10-Q · filed 2020-11-09 | -$55.30M derived: sum of 4 quarters · filed 2020-11-09 | |
| 2019-06-30 | -$14.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$32.49M 10-Q · filed 2020-08-10 | -$42.77M derived: sum of 3 quarters · filed 2020-08-10 | -$52.05M derived: sum of 4 quarters · filed 2020-08-10 | |
| 2019-03-31 | -$17.93M 10-Q · filed 2020-05-07 | -$28.22M derived: sum of 2 quarters · filed 2020-05-07 | -$37.50M derived: sum of 3 quarters · filed 2020-05-07 | -$45.64M derived: sum of 4 quarters · filed 2020-05-07 | |
| 2018-12-31 | -$10.28M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$19.56M derived: sum of 2 quarters · filed 2020-03-02 | -$27.71M derived: sum of 3 quarters · filed 2020-03-02 | -$37.33M 10-K · filed 2020-03-02 | |
| 2018-09-30 | -$9.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$17.43M derived: sum of 2 quarters · filed 2019-11-12 | -$27.05M 10-Q · filed 2019-11-12 | -$33.01M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-06-30 | -$8.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$17.77M 10-Q · filed 2019-08-09 | -$23.73M derived: sum of 3 quarters · filed 2020-03-02 | -$21.13M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-03-31 | -$9.62M 10-Q · filed 2019-05-09 | -$15.58M derived: sum of 2 quarters · filed 2020-03-02 | -$12.99M derived: sum of 3 quarters · filed 2020-03-02 | -$16.45M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2017-12-31 | -$5.96M derived: 10-K 12 month − 6-K 9 month · filed 2020-03-02 | -$3.36M derived: sum of 2 quarters · filed 2020-03-02 | -$6.82M derived: sum of 3 quarters · filed 2020-03-02 | -$9.57M 10-K · filed 2020-03-02 | -$9.57M 20-F · filed 2018-03-15 |
| 2017-09-30 | $2.60M derived: 6-K 9 month − 6-K 6 month · filed 2018-11-13 | -$864.00K derived: sum of 2 quarters · filed 2018-11-13 | -$3.61M 6-K · filed 2018-11-13 | ||
| 2017-06-30 | -$3.46M derived: 6-K 6 month − 6-K 3 month · filed 2018-08-14 | -$6.21M 6-K · filed 2018-08-14 | |||
| 2017-03-31 | -$2.75M 6-K · filed 2018-05-15 | ||||
| 2016-12-31 | $4.19M 10-K · filed 2019-02-28 | ||||
| 2015-12-31 | -$7.17M 20-F · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |